
1. Technology overview
Edison Scientific presents itself as the AI platform for scientific R&D, run by scientists and engineers across physics, biology, chemistry and AI. Its legal entity is Edison Scientific, Inc., and its research lineage includes ChemCrow, PaperQA, Aviary and the Robin agent published in Nature.
Kosmos drives investigations by reading literature, analyzing data, generating hypotheses and running workflows, and supports drug development from target identification to filing. The Edison platform deploys agents across the R&D pipeline with on-prem options, SOC 2 Type II compliance and forward-deployed scientists.
2. Highlighted features & specifications
- Kosmos AI scientist: reads literature, analyzes data, generates hypotheses and runs workflows.
- Drug development support: covers target identification through clinical development and filing.
- Edison platform: deploys agents across the R&D pipeline with custom world models.
- Collaboration integrations: connects with Slack, Teams and email.
- Enterprise controls: on-prem options, SOC 2 Type II and a trust center.
3. Potential application
Literature and patent review for pharma R&D teams. Hypothesis generation for university research groups. Regulatory document preparation support for biotech start-ups.
4. Benefits
Automates literature review, data analysis and hypothesis generation in one agent workflow. Integrates with Slack, Teams and email so researchers work in existing tools. On-prem deployment and SOC 2 Type II compliance address data security needs. Forward-deployed scientists help customers adapt the platform.
5. Market trends & opportunities
AI scientist agents are moving from research demos to enterprise R&D tools, with pharma partnerships and publisher data integrations. Vietnamese pharmaceutical, biotech and university labs can use literature-and-data agents to cope with limited research staff.
6. Other information
Edison Scientific, Inc. Named customers and partners on the site include Pfizer, Incyte, Population Health Partners, Springer Nature, MIT and the Broad Institute. Announcements: Incyte partnership (May 2026), Population Health Partners (June 2026), Springer Nature (September 2026), Pfizer agreement (October 2026).
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE








































